3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
7
Hodgkin Disease
6
Lymphoma, Large B-Cell, Diffuse
5
Triple Negative Breast Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Rhabdomyosarcoma
3
Lymphoma, Non-Hodgkin
3
Leukemia
3
Burkitt Lymphoma
3
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neuroblastoma
2
Multiple Myeloma
2
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Teratoma
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Initiation and Maintenance Disorders
1
Sarcoma, Ewing
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Pain
1
Interventions
Trastuzumab
14
pertuzumab
10
Docetaxel
7
tucatinib
4
pyrotinib
4
Paclitaxel
4
Capecitabine
4
Carboplatin
2
Ado-Trastuzumab Emtansine
2
trastuzumab deruxtecan
1
pegfilgrastim
1
neratinib
1
exemestane
1
dalpiciclib
1
atezolizumab
1
Neoadjuvant Therapy
1
Leuprolide
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Goserelin
1
Genetic Testing
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Blood Specimen Collection
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Breast Cancer
×
pegfilgrastim
×
1 year
×
Clear all
NCT03571633
2025-11-26
BREASTIMMU02
Centre Leon Berard
Phase 2
Active not recruiting
90 enrolled